Description

Retatrutide 60mg UAE is a product listing associated with retatrutide, an investigational compound being studied in clinical research. Retatrutide is also known by the development code LY3437943 and is being investigated as a triple receptor agonist involving the GIP, GLP-1 and glucagon pathways.

The compound has attracted substantial scientific interest because researchers are evaluating whether activity across these three receptor systems can influence body weight, metabolic health and other clinical outcomes.

Clinical research on retatrutide has progressed into Phase 3 and Phase 3b studies. Current ClinicalTrials.gov records include studies evaluating weight reduction, maintenance of weight reduction, safety and different dose-escalation approaches.

The Pureness X page currently lists a Retatrutide 60 mg product with a displayed price of AED 950. This is the price shown on the online product listing and should not be interpreted as an official UAE medicine price.

What Is Retatrutide?

Retatrutide, also known as LY3437943, is an investigational compound being developed for metabolic-health research.

Its distinguishing scientific characteristic is activity across three receptor pathways:

• GLP-1 receptor

• GIP receptor

• Glucagon receptor

Because of this combination, retatrutide is commonly described as a triple agonist.

The compound is being studied in clinical trials involving obesity and overweight populations, among other research areas. ClinicalTrials.gov currently lists Phase 3 and Phase 3b retatrutide studies.

Retatrutide 60mg UAE Product Information

The Pureness X listing currently identifies this product as Retatrutide 60 mg and displays a price of AED 950.

Product Information

The product-page information above reflects the current online listing and does not establish regulatory approval, clinical equivalence or product authenticity.

How Does the Retatrutide Triple-Agonist Approach Work?

Retatrutide is being investigated because it interacts with three hormone-related receptor pathways.

GLP-1 Pathway

GLP-1 signalling is associated with appetite regulation, satiety and glucose-related physiological processes.

GIP Pathway

GIP is involved in glucose-dependent insulin signalling and metabolic processes.

Glucagon Pathway

Glucagon is involved in energy metabolism and regulation of stored energy.

Researchers are investigating whether combining these three pathways can produce meaningful changes in body weight and metabolic measures.

The triple-agonist mechanism is one of the major scientific features that distinguishes retatrutide from compounds acting primarily through a single receptor pathway.

Retatrutide Clinical Research

Retatrutide has progressed into later-stage clinical development.

ClinicalTrials.gov currently lists several Phase 3 and Phase 3b studies.

For example, TRIUMPH-6 is a Phase 3b study examining maintenance of weight reduction in people with obesity.

TRIUMPH-8 is a Phase 3b study evaluating the efficacy and safety of retatrutide in people with obesity or overweight without type 2 diabetes.

TRIUMPH-9 is another Phase 3 study examining different dose-escalation approaches in participants with obesity or overweight who do not have type 2 diabetes.

There is also a Phase 3 study comparing retatrutide with tirzepatide in adults with obesity.

These studies demonstrate ongoing clinical development. They do not mean that retatrutide has already become an approved medicine in every market.

Retatrutide and Weight-Loss Research

One of the main areas of retatrutide research is body-weight reduction.

Researchers are examining:

• Changes in body weight

• Weight-maintenance outcomes

• Metabolic measurements

• Safety and tolerability

• Differences between research groups

• Longer-term treatment outcomes

The scientific purpose of clinical trials is to determine whether observed effects are meaningful, reproducible and sufficiently safe.

Individual results cannot be predicted from clinical-trial data alone.

Retatrutide vs GLP-1 Research

Retatrutide is sometimes discussed alongside GLP-1 medicines because one of its receptor targets is GLP-1.

However, retatrutide is not simply a GLP-1-only compound.

This three-pathway activity is the central scientific feature behind the term triple agonist.

What Is LY3437943?

LY3437943 is the development code associated with retatrutide.

Researchers and people following clinical development may encounter both terms:

Retatrutide

and

LY3437943

in clinical-trial records and scientific literature.

For example, ClinicalTrials.gov uses “Retatrutide (LY3437943)” in multiple study records.

This makes LY3437943 an important secondary research keyword for an informational page.

Retatrutide Phase 3 Development

Phase 3 research represents a later stage of clinical development.

Current ClinicalTrials.gov records show retatrutide being evaluated in multiple Phase 3 and Phase 3b studies. These studies are examining different populations and outcomes, including weight reduction, weight maintenance and safety.

The existence of Phase 3 trials should not be interpreted as proof of regulatory approval.

Clinical development and regulatory authorization are separate processes.

Retatrutide UAE Regulatory Status

This section is very important for your UAE SEO page.

The Abu Dhabi Department of Health issued Circular No. 40/2026 on 6 March 2026, warning healthcare facilities, healthcare professionals and the public against an unauthorized medical product identified as “Retatrutide.” The circular states that the product was being promoted online and that retatrutide remained under clinical development, with no authorized supply or legitimate distribution in global markets.

Therefore, an online listing should not be presented as proof that retatrutide is an approved UAE medicine.

Important distinction

Online product listing ≠ regulatory approval

Clinical trial ≠ medicine authorization

Listed price ≠ official UAE medicine price

Product description ≠ proof of authenticity

This distinction is particularly important for anyone searching for Retatrutide 60mg UAE.

Is Retatrutide Approved in the UAE?

Based on the March 2026 Abu Dhabi Department of Health circular, retatrutide was identified as an unauthorized medical product and the authority warned against its use. The circular states that retatrutide remains under clinical development.

For this reason, this product page should not claim that retatrutide is an approved UAE weight-loss medicine or routinely available through UAE pharmacies.

What Should Be Checked When Researching a Peptide Product?

People researching an online product listing should independently verify relevant information.

Important areas include:

Product identity

Confirm the stated compound and strength.

Batch information

Check whether a specific batch or lot number is provided.

Laboratory documentation

Review available laboratory documentation and determine exactly what was tested.

Certificate of Analysis

Where a COA is provided, check whether it relates to the actual batch.

Supplier information

Verify the identity and provenance of the supplier.

Regulatory status

Check the latest requirements and warnings from the relevant UAE authority.

Intended use

Do not automatically assume that an online research-product listing is equivalent to an approved pharmaceutical product.

Retatrutide 60mg Price in UAE

The current Pureness X product page displays AED 950 for Retatrutide 60 mg.

For SEO purposes, it is reasonable to provide the current listed price, but it should be described as an online listing price rather than an official regulated medicine price.

If the Shopify price changes later, remember to update the text if you have manually mentioned AED 950 inside the description.

Retatrutide Safety Research

Safety evaluation remains an important component of retatrutide clinical development.

Clinical studies examine both potential effects and adverse events while monitoring participants under defined research protocols.

Research questions can include:

• Overall tolerability

• Gastrointestinal adverse events

• Metabolic measurements

• Cardiovascular outcomes

• Treatment discontinuation

• Longer-term safety

Because retatrutide remains investigational, research findings should not be converted into individual medical recommendations.

Frequently Asked Questions

What is Retatrutide 60mg?

Retatrutide is an investigational compound also known as LY3437943. The Pureness X page currently lists a product identified as Retatrutide 60 mg.

What is LY3437943?

LY3437943 is the development code associated with retatrutide and is used in clinical research records.

What does triple agonist mean?

It refers to retatrutide's investigation across three receptor pathways: GLP-1, GIP and glucagon.

Is retatrutide approved in the UAE?

The Abu Dhabi Department of Health issued a March 2026 warning identifying retatrutide as an unauthorized medical product and stating that it remains under clinical development.

What is the listed price of Retatrutide 60mg UAE?

The Pureness X page currently displays AED 950. This is an online listing price, not an official regulated UAE medicine price.

Is retatrutide a GLP-1-only compound?

No. Retatrutide is being investigated as a triple agonist involving GLP-1, GIP and glucagon pathways.

Is Retatrutide in Phase 3?

Yes. Current ClinicalTrials.gov records show Phase 3 and Phase 3b retatrutide studies.

Research & Regulatory Disclaimer

This content is provided for educational and research-information purposes only.

Retatrutide remains an investigational compound and should not be represented as an approved UAE medicine.

This page does not provide individualized medical advice, dosing instructions, injection instructions or treatment recommendations.

An online product listing does not establish regulatory approval, authenticity, purity, safety or suitability for human use.

Always verify current UAE regulatory information and consult a qualified healthcare professional for medical questions.